| Business Summary | | TriPath
Imaging,
Inc.
develops,
manufactures
and
markets
proprietary
products
for
cancer
cell
diagnosis,
cytology
and
histopathology.
TriPath
Imaging
manufactures
and
sells
products
developed
from
its
proprietary
technologies
and
intellectual
property.
These
include
United
States
Food
and
Drug
Administration
(FDA)-approved
products
designed
to
automate
the
screening
for
cancer
of
the
uterine
cervix,
including
the
AutoCyte
Prep
System
and
the
AutoPap
Primary
Screening
System.
In
addition,
the
Company
has
developed
the
extended
Slide
Wizard
line
of
products,
the
modules
for
which
include
an
FDA-approved
method
for
automating
measurement
of
antinuclear
antibodies,
as
well
as
research
applications
in
histopathology,
a
system
for
the
transmission
and
interpretation
of
tissue
specimens
via
remote
telecommunication
and
the
AutoCyte
Image
Management
and
Archiving
System,
a
software
based
storage
and
retrieval
system
for
microscopic
images. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | TriPath
Imaging
develops,
manufactures
and
markets
the
only
integrated
automated
sample
preparation
and
image
analysis
system
to
support
cytology
professionals
in
cervical
cancer
screening.
For
the
six
months
ended
6/30/01,
net
sales
fell
less
than
1%
to
$15.4
million.
Net
loss
fell
6%
to
$7.4
million.
Revenues
reflect
reduced
AutoPap
related
sales.
Lower
loss
reflects
decreased
general/administrative
expenses
and
reduced
interest
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| James Powell, M.D., 61 Chairman | $181K | -- | Paul Sohmer Pres, CEO | -- | -- | David Robison, 49 VP
of Operations | 170K | -- | Roger Martin, 52 VP,
Sales and Marketing | -- | -- | Thomas Gahm, Ph.D., 43 VP
of Cytology R&D | 178K | $128K | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|